Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PULMATRIX, INC.

(PULM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pulmatrix : to Regain Full Rights to Narrow Spectrum Kinase Inhibitor Portfolio After Johnson & Johnson Deal Termination

04/12/2021 | 10:58am EDT


© MT Newswires 2021
All news about PULMATRIX, INC.
04/13PULMATRIX  : Other Events, Financial Statements and Exhibits (form 8-K/A)
AQ
04/13UPDATE : Pulmatrix Shares Down Again After Johnson & Johnson Ends Development De..
MT
04/13PULMATRIX  : HC Wainwright Adjusts Pulmatrix' Price Target to $5 From $10, Keeps..
MT
04/12CORRECTED : Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinas..
PR
04/12PULMATRIX  : to Regain Full Rights to Narrow Spectrum Kinase Inhibitor Portfolio..
MT
04/12PULMATRIX, INC.  : Termination of a Material Definitive Agreement, Regulation FD..
AQ
04/12PULMATRIX  : to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibit..
PR
04/12PULMATRIX  : J&J Terminates License, Development, Commercialization Pact
DJ
04/05PULMATRIX, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
03/23PULMATRIX  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
More news
Financials (USD)
Sales 2021 2,00 M - -
Net income 2021 -20,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,37x
Yield 2021 -
Capitalization 49,4 M 49,4 M -
Capi. / Sales 2021 24,7x
Capi. / Sales 2022 -
Nbr of Employees 21
Free-Float 60,5%
Chart PULMATRIX, INC.
Duration : Period :
Pulmatrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULMATRIX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 5,00 $
Last Close Price 0,88 $
Spread / Highest target 469%
Spread / Average Target 469%
Spread / Lowest Target 469%
EPS Revisions
Managers and Directors
NameTitle
Teofilo Raad President, Chief Executive Officer & Director
Michelle Siegert Secretary, Treasurer & Vice President-Finance
Michael John Higgins Chairman
Aidan Curran Head-Research
Mark T. Iwicki Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX, INC.-26.22%49
GILEAD SCIENCES, INC.14.16%83 740
WUXI APPTEC CO., LTD.10.67%59 429
VERTEX PHARMACEUTICALS-9.81%55 364
REGENERON PHARMACEUTICALS-0.14%49 948
BIONTECH SE106.08%41 245